These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

768 related items for PubMed ID: 25369108

  • 1. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Wetzels JF, Drenth JP.
    Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
    [Abstract] [Full Text] [Related]

  • 2. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
    Gevers TJ, Chrispijn M, Wetzels JF, Drenth JP.
    BMC Nephrol; 2012 Apr 04; 13():17. PubMed ID: 22475206
    [Abstract] [Full Text] [Related]

  • 3. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
    van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH, DIPAK-1 Investigators.
    Gastroenterology; 2019 Aug 04; 157(2):481-491.e7. PubMed ID: 31022403
    [Abstract] [Full Text] [Related]

  • 4. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
    Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D'Agnolo HMA, Dekker SEI, Drenth JPH, de Fijter JW, van Gastel MDA, Gevers TJ, Lantinga MA, Losekoot M, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Wetzels JF, Zietse R, Gansevoort RT, DIPAK-1 Investigators.
    JAMA; 2018 Nov 20; 320(19):2010-2019. PubMed ID: 30422235
    [Abstract] [Full Text] [Related]

  • 5. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
    Meijer E, Drenth JP, d'Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, DIPAK Consortium.
    Am J Kidney Dis; 2014 Mar 20; 63(3):446-55. PubMed ID: 24342522
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
    van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP.
    Gastroenterology; 2009 Nov 20; 137(5):1661-8.e1-2. PubMed ID: 19646443
    [Abstract] [Full Text] [Related]

  • 8. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
    Hogan MC, Chamberlin JA, Vaughan LE, Waits AL, Banks C, Leistikow K, Oftsie T, Madsen C, Edwards M, Glockner J, Kremers WK, Harris PC, LaRusso NF, Torres VE, Masyuk TV.
    Clin J Am Soc Nephrol; 2020 Sep 07; 15(9):1267-1278. PubMed ID: 32843370
    [Abstract] [Full Text] [Related]

  • 9. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis.
    Gevers TJ, Nevens F, Torres VE, Hogan MC, Drenth JP.
    Liver Int; 2016 Apr 07; 36(4):595-602. PubMed ID: 26481454
    [Abstract] [Full Text] [Related]

  • 10. The long-term outcome of patients with polycystic liver disease treated with lanreotide.
    Chrispijn M, Nevens F, Gevers TJ, Vanslembrouck R, van Oijen MG, Coudyzer W, Hoffmann AL, Dekker HM, de Man RA, van Keimpema L, Drenth JP.
    Aliment Pharmacol Ther; 2012 Jan 07; 35(2):266-74. PubMed ID: 22111942
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data.
    Gevers TJ, Inthout J, Caroli A, Ruggenenti P, Hogan MC, Torres VE, Nevens F, Drenth JP.
    Gastroenterology; 2013 Aug 07; 145(2):357-65.e1-2. PubMed ID: 23665274
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL, Meijer E, Visser FW, Engels GE, Kappert P, Losekoot M, Peters DJM, Gansevoort RT, on behalf of the DIPAK-1 study investigators.
    Am J Nephrol; 2019 Aug 07; 50(5):375-385. PubMed ID: 31600749
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.
    Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP.
    J Hepatol; 2013 Jul 07; 59(1):153-9. PubMed ID: 23499726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.